Biocon and Mylan submit application for biosimilar cancer drug trastuzumab in US

Biocon and Mylan submit application for biosimilar cancer drug trastuzumab in US
NV and Ltd announced submission of Mylan’s biologics license application (BLA) for MYL-1401O, a proposed trastuzumab, to the US Food and Administration (FDA) through the 351 (K) pathway. This product is a proposed to branded trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers. and believe that this has the potential to be the first submission of a proposed in the US.

“The submission of our proposed with the US FDA is an important milestone of and Mylan’s joint global biosimilars program and demonstrates our commitment to provide access to high-quality and affordable biologics to patients across the globe. patients in India and emerging markets have benefited with our and this advancement in the US will enable us to enhance access to this affordable therapy to larger patient pools,” said Dr Arun Chandavarkar, CEO & joint MD, Biocon.

Rajiv Malik, president, Mylan, added, “The FDA submission for marks Mylan’s first FDA submission from our broad portfolio of products in development and our product has the opportunity to be the first approved in the US. This submission also is another demonstration of the strength of the Mylan- partnership and our shared commitment to increasing access to these critical medicines worldwide. Our is already being sold in 11 developing markets, including India, and we look forward to bringing the product to market in the US and Europe upon approval.”

The submitted BLA includes a comprehensive package of analytical similarity, nonclinical and clinical data. The clinical data consists of two pharmacokinetic studies and the HERITAGE confirmatory efficacy and safety trial. The results of the HERITAGE trial were presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress.

and are exclusive partners on a broad portfolio of and insulin products. The proposed is one of the six biologic products co-developed by and for the global marketplace. has exclusive commercialisation rights for the proposed in the US, Canada, Japan, Australia, New Zealand and in the European Union and European Free Trade Association countries. has co-exclusive commercialisation rights with for the product in the rest of the world.

Leave a Reply